| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PCRX | Common Stock | Options Exercise | $100,533 | +9,300 | +61% | $10.81 | 24,452 | 10 Mar 2022 | Direct | |
| transaction | PCRX | Common Stock | Sale | $597,576 | -8,400 | -34% | $71.14 | 16,052 | 10 Mar 2022 | Direct | F1 |
| transaction | PCRX | Common Stock | Sale | $64,755 | -900 | -5.6% | $71.95 | 15,152 | 10 Mar 2022 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PCRX | Stock Option (Right to Buy) | Options Exercise | $0 | -9,300 | -100% | $0.000000* | 0 | 10 Mar 2022 | Common Stock | 9,300 | $10.81 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.84 to $71.74, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.895 to $72.005, inclusive. |
| F3 | The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. |